Journal
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
Volume 11, Issue 4, Pages -Publisher
COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/cshperspect.a038240
Keywords
-
Categories
Funding
- NCI NIH HHS [K08 CA237832, P30 CA008748] Funding Source: Medline
Ask authors/readers for more resources
In recent years, there has been a renewed interest in the biology and therapeutic vulnerabilities of small-cell lung cancer (SCLC), leading to the development of diverse models and translational research avenues. These offer new hope for patients with SCLC by combining mechanism-based preclinical and clinical research.
Over the past several years, we have witnessed a resurgence of interest in the biology and therapeutic vulnerabilities of small-cell lung cancer (SCLC). This has been driven in part through the development of a more extensive array of representative models of disease, including a diverse variety of genetically engineered mouse models and human tumor xenografts. Herein, we review recent progress in SCLC model development, and consider some of the particularly active avenues of translational research in SCLC, including interrogation of intratumoral heterogeneity, insights into the cell of origin and oncogenic drivers, mechanisms of chemoresistance, and new therapeutic opportunities including biomarker-directed targeted therapies and immunotherapies. Whereas SCLC remains a highly lethal disease, these new avenues of translational research, bringing together mechanism-based preclinical and clinical research, offer new hope for patients with SCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available